The webinar “Listing Biotech Companies in Hong Kong” provides an in-depth overview of the regulatory framework that allows pre-revenue biotech companies to list on the Hong Kong Stock Exchange under Chapter 18A of the Main Board Listing Rules. It examines the development of the biotech listing regime, the growth of the biotech sector in China, and Hong Kong’s role as a major fundraising hub, alongside key eligibility, disclosure, and ongoing compliance requirements for biotech issuers.

Topics covered in the webinar recording:

• Background and evolution of the Chapter 18A biotech listing regime
• Growth trends in the biotech sector and Hong Kong’s position as a funding centre
• Core Product eligibility and development milestone requirements
• Suitability criteria for pre-revenue biotech listing applicants
• Market capitalisation, working capital, and public float thresholds
• Listing document disclosure obligations for biotech companies
• Modified continuing obligations for Chapter 18A issuers
• Recent regulatory developments, including TECH and confidential filing

Access the video here.